These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Pharmacological issues in the treatment of bipolar disorder: focus on mood-stabilizing compounds. Potter WZ; Ketter TA Can J Psychiatry; 1993 Apr; 38(3 Suppl 2):S51-6. PubMed ID: 8500079 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and therapeutic drug monitoring of psychotropic drugs in pediatrics. Pichini S; Papaseit E; Joya X; Vall O; Farré M; Garcia-Algar O; de laTorre R Ther Drug Monit; 2009 Jun; 31(3):283-318. PubMed ID: 19363463 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder. Kilbourne AM; Post EP; Bauer MS; Zeber JE; Copeland LA; Good CB; Pincus HA J Affect Disord; 2007 Sep; 102(1-3):145-51. PubMed ID: 17276514 [TBL] [Abstract][Full Text] [Related]
8. Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder. Ketter TA J Clin Psychiatry; 2008; 69 Suppl 5():9-15. PubMed ID: 19265635 [TBL] [Abstract][Full Text] [Related]
9. Introduction: the use of mood stabilizers in the treatment of psychiatric disorders. Bowden CL J Clin Psychiatry; 1999; 60 Suppl 5():3-4. PubMed ID: 10192401 [No Abstract] [Full Text] [Related]
10. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. Kane JM; Leucht S; Carpenter D; Docherty JP; J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142 [TBL] [Abstract][Full Text] [Related]
11. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia. Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734 [TBL] [Abstract][Full Text] [Related]
13. [Are mood stabilizers beneficial in the treatment of schizophrenia?]. Berle JØ; Spigset O Tidsskr Nor Laegeforen; 2005 Jun; 125(13):1809-12. PubMed ID: 16012547 [TBL] [Abstract][Full Text] [Related]
14. Individual clearance and therapeutic drug monitoring of quetiapine in clinical practice. Wittmann M; Hausner H; Köstlbacher A; Hajak G; Haen E Neuro Endocrinol Lett; 2010; 31(2):203-7. PubMed ID: 20424588 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic drug-drug interactions between olanzapine and valproate need to be better studied. de Leon J; Diaz FJ; Spina E J Clin Psychiatry; 2010 Jul; 71(7):957-8; author reply 958-9. PubMed ID: 20667295 [No Abstract] [Full Text] [Related]
16. Metabolic drug interactions with newer antipsychotics: a comparative review. Spina E; de Leon J Basic Clin Pharmacol Toxicol; 2007 Jan; 100(1):4-22. PubMed ID: 17214606 [TBL] [Abstract][Full Text] [Related]
18. [Antiepileptic drugs as mood stabilizers: what did we learn from the epileptology?]. Rajna P Ideggyogy Sz; 2008 Sep; 61(9-10):305-16. PubMed ID: 18841650 [TBL] [Abstract][Full Text] [Related]